vs
Side-by-side financial comparison of MAXLINEAR, INC (MXL) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
MAXLINEAR, INC is the larger business by last-quarter revenue ($137.2M vs $75.5M, roughly 1.8× PUMA BIOTECHNOLOGY, INC.). On growth, MAXLINEAR, INC posted the faster year-over-year revenue change (43.0% vs 27.7%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 22.1%).
MaxLinear, Inc. is an American electronic hardware company. Founded in 2003, it provides highly integrated radio-frequency (RF) analog and mixed-signal semiconductor products for broadband communications applications. It is a New York Stock Exchange-traded company.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
MXL vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $137.2M | $75.5M |
| Net Profit | $-45.1M | — |
| Gross Margin | 57.5% | 69.3% |
| Operating Margin | 30.0% | 22.7% |
| Net Margin | -32.9% | — |
| Revenue YoY | 43.0% | 27.7% |
| Net Profit YoY | -203.0% | — |
| EPS (diluted) | $-0.52 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $137.2M | — | ||
| Q4 25 | $136.4M | $75.5M | ||
| Q3 25 | $126.5M | $54.5M | ||
| Q2 25 | $108.8M | $52.4M | ||
| Q1 25 | $95.9M | $46.0M | ||
| Q4 24 | $92.2M | $59.1M | ||
| Q3 24 | $81.1M | $80.5M | ||
| Q2 24 | $92.0M | $47.1M |
| Q1 26 | $-45.1M | — | ||
| Q4 25 | $-14.9M | — | ||
| Q3 25 | $-45.5M | $8.8M | ||
| Q2 25 | $-26.6M | $5.9M | ||
| Q1 25 | $-49.7M | $3.0M | ||
| Q4 24 | $-57.8M | — | ||
| Q3 24 | $-75.8M | $20.3M | ||
| Q2 24 | $-39.3M | $-4.5M |
| Q1 26 | 57.5% | — | ||
| Q4 25 | 57.6% | 69.3% | ||
| Q3 25 | 56.9% | 77.7% | ||
| Q2 25 | 56.5% | 76.5% | ||
| Q1 25 | 56.1% | 77.1% | ||
| Q4 24 | 55.6% | 76.4% | ||
| Q3 24 | 54.4% | 63.9% | ||
| Q2 24 | 54.6% | 77.4% |
| Q1 26 | 30.0% | — | ||
| Q4 25 | -10.9% | 22.7% | ||
| Q3 25 | -32.7% | 17.6% | ||
| Q2 25 | -22.6% | 12.7% | ||
| Q1 25 | -48.0% | 8.7% | ||
| Q4 24 | -44.7% | 22.6% | ||
| Q3 24 | -82.3% | 27.4% | ||
| Q2 24 | -44.4% | -4.6% |
| Q1 26 | -32.9% | — | ||
| Q4 25 | -10.9% | — | ||
| Q3 25 | -36.0% | 16.2% | ||
| Q2 25 | -24.4% | 11.2% | ||
| Q1 25 | -51.8% | 6.5% | ||
| Q4 24 | -62.8% | — | ||
| Q3 24 | -93.4% | 25.2% | ||
| Q2 24 | -42.7% | -9.6% |
| Q1 26 | $-0.52 | — | ||
| Q4 25 | $-0.17 | $0.26 | ||
| Q3 25 | $-0.52 | $0.17 | ||
| Q2 25 | $-0.31 | $0.12 | ||
| Q1 25 | $-0.58 | $0.06 | ||
| Q4 24 | $-0.68 | $0.40 | ||
| Q3 24 | $-0.90 | $0.41 | ||
| Q2 24 | $-0.47 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $61.1M | $97.5M |
| Total DebtLower is stronger | $123.8M | $22.7M |
| Stockholders' EquityBook value | $454.2M | $130.3M |
| Total Assets | $771.3M | $216.3M |
| Debt / EquityLower = less leverage | 0.27× | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $61.1M | — | ||
| Q4 25 | $72.8M | $97.5M | ||
| Q3 25 | $111.9M | $94.4M | ||
| Q2 25 | $108.6M | $96.0M | ||
| Q1 25 | $102.8M | $93.2M | ||
| Q4 24 | $118.6M | $101.0M | ||
| Q3 24 | $148.5M | $96.7M | ||
| Q2 24 | $185.1M | $96.8M |
| Q1 26 | $123.8M | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M |
| Q1 26 | $454.2M | — | ||
| Q4 25 | $451.9M | $130.3M | ||
| Q3 25 | $464.7M | $115.3M | ||
| Q2 25 | $488.3M | $104.7M | ||
| Q1 25 | $493.2M | $97.1M | ||
| Q4 24 | $516.3M | $92.1M | ||
| Q3 24 | $556.9M | $71.1M | ||
| Q2 24 | $617.3M | $48.5M |
| Q1 26 | $771.3M | — | ||
| Q4 25 | $796.4M | $216.3M | ||
| Q3 25 | $808.1M | $202.9M | ||
| Q2 25 | $863.7M | $194.9M | ||
| Q1 25 | $855.3M | $196.2M | ||
| Q4 24 | $864.6M | $213.3M | ||
| Q3 24 | $895.3M | $220.7M | ||
| Q2 24 | $973.2M | $205.0M |
| Q1 26 | 0.27× | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $10.4M | $14.4M | ||
| Q3 25 | $10.1M | $9.7M | ||
| Q2 25 | $10.5M | $14.1M | ||
| Q1 25 | $-11.4M | $3.6M | ||
| Q4 24 | $-27.8M | $15.6M | ||
| Q3 24 | $-30.7M | $11.0M | ||
| Q2 24 | $-2.7M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | $6.7M | $14.4M | ||
| Q3 25 | $4.4M | $9.7M | ||
| Q2 25 | $9.3M | $14.1M | ||
| Q1 25 | $-13.4M | $3.6M | ||
| Q4 24 | $-30.0M | $15.6M | ||
| Q3 24 | $-34.9M | $11.0M | ||
| Q2 24 | $-5.7M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 19.1% | ||
| Q3 25 | 3.5% | 17.7% | ||
| Q2 25 | 8.6% | 26.8% | ||
| Q1 25 | -14.0% | 7.7% | ||
| Q4 24 | -32.6% | 26.4% | ||
| Q3 24 | -43.0% | 13.7% | ||
| Q2 24 | -6.2% | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 0.0% | ||
| Q3 25 | 4.5% | 0.0% | ||
| Q2 25 | 1.1% | 0.0% | ||
| Q1 25 | 2.1% | 0.1% | ||
| Q4 24 | 2.4% | 0.0% | ||
| Q3 24 | 5.1% | 0.0% | ||
| Q2 24 | 3.3% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
